Pelthos Q3 Zelsuvmi revenue jumps 114%, net loss narrows
PTHS•PTHS•PTHS•PTHS•Pelthos said third-quarter Zelsuvmi revenue rose 114% year over year to $15.2 million, while its net loss narrowed to $7.9 million from $16.2 million. The company expects its merger with Castle Creek to close by the end of the first quarter of 2027.
Pelthos reported third-quarter Zelsuvmi revenue of $15.2 million, up 114% year over year. The company attributed growth to increased use by healthcare providers and expanded access, including formulary coverage reaching 127 million commercially covered lives and strong Medicaid coverage. Its net loss narrowed to $7.9 million from $16.2 million a year earlier; adjusted EBITDA was negative $5.6 million.
Pelthos expects continued Zelsuvmi growth as coverage and access expand. It targets an Xepi launch in the first quarter of 2027 and an Xeglyze launch in the third quarter of 2027. The company expects its merger with Castle Creek to close by the end of the first quarter of 2027.
